Anti‑neoplastic effect of mangiferin on human ovarian adenocarcinoma OVCAR8 cells via the regulation of YAP

He,Wenjing; You,Yaodong; Du,Suya; Lei,Tiantian; Wang,Hailian; Li,Xiang; He,Xia; Tong,Rongsheng; Wang,Yi

doi:10.3892/ol.2018.9708

Anti‑neoplastic effect of mangiferin on human ovarian adenocarcinoma OVCAR8 cells via the regulation of YAP

Authors:
- Wenjing He
- Yaodong You
- Suya Du
- Tiantian Lei
- Hailian Wang
- Xiang Li
- Xia He
- Rongsheng Tong
- Yi Wang
View Affiliations

Affiliations: Department of Gynecology, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China, Clinical Medical College of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, P.R. China, Department of Pharmacy, Chengdu Military General Hospital, Chengdu, Sichuan 610083, P.R. China, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, P.R. China, Institute of Organ Transplantation, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China, Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China
Published online on: November 15, 2018 https://doi.org/10.3892/ol.2018.9708
Pages: 1008-1018
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is the most malignant gynecologic neoplasm in women and has the worst prognosis of all cancer types in women based on the 5‑year survival rates. A previous study indicated that mangiferin exerts an anti‑neoplastic effect on human ovarian cancer cells by targeting Notch3. Additionally, it has been demonstrated that Notch signaling is a functionally important downstream effector of Yes‑associated protein (YAP), therefore it was hypothesized that YAP may be involved in the antitumor effect of mangiferin. The present study aimed to further reveal the mangiferin‑mediated inhibitory effect on ovarian cancer and investigate the molecular anticancer mechanism of mangiferin. Based on the in vitro data, accompanied with the significantly reduced cell proliferation of mangiferin‑treated cells compared with mangiferin‑treated YAP‑overexpressed cells (P<0.05), YAP expression was identified to be substantially downregulated by mangiferin. In contrast, observations of the cell morphology and apoptotic percentages revealed that the antitumor effect of mangiferin may be reversed by YAP overexpression. Furthermore, decreased levels of migration and invasion were observed in mangiferin‑treated cells, which may also be abrogated by YAP overexpression. Thus, these data further demonstrated that mangiferin inhibits metastasis by regulating YAP. Additionally, due to the frequent chemoresistance observed in cisplatin‑based chemotherapy, the present study evaluated the cisplatin resistance in OVCAR8 cells and elucidated that mangiferin may sensitize the tumor cells to cisplatin; and this improved sensitization was also abolished by YAP overexpression. These results collectively indicated that YAP was not only closely associated with the anticancer effect of mangiferin, but also mediated drug resistance in tumor. Furthermore, the downregulation of downstream TEA domain transcription factor 4 expression was observed in the mangiferin‑treated cells, further validating the inhibitory effect of mangiferin on YAP. In addition, OVCAR8 cell xenograft models revealed that through increasing the sensitivity of a tumor to cisplatin, mangiferin inhibited the growth of a tumor and increased the survival time of tumor xenograft mice. Based on these results, it was concluded that mangiferin may inhibit tumor cell growth and enhance cisplatin‑sensitivity in OVCAR8 cells via the regulation of the YAP pathway. Altogether, by targeting YAP and enhancing the response to cisplatin treatment, mangiferin potentially functioned as a novel therapeutic agent in the treatment of ovarian cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. Ca Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Hennessy BT, Coleman RL and Markman M: Ovarian cancer. Lancet. 374:13712009. View Article : Google Scholar : PubMed/NCBI
3	Cai H and Xu Y: The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. Cell Commun Signal. 11:312013. View Article : Google Scholar : PubMed/NCBI
4	Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S and Goode S: Hippo pathway effector yap is an ovarian cancer oncogene. Cancer Res. 70:8517–8525. 2010. View Article : Google Scholar : PubMed/NCBI
5	Arend RC, Londoño-Joshi AI, Straughn JM Jr and Buchsbaum DJ: The Wnt/β-catenin pathway in ovarian cancer: A review. Gynecol Oncol. 131:772–779. 2013. View Article : Google Scholar : PubMed/NCBI
6	Takebe N, Harris PJ, Warren RQ and Ivy SP: Targeting cancer stem cells by inhibiting wnt, notch, and hedgehog pathways. Nat Rev Clin Oncol. 8:97–106. 2011. View Article : Google Scholar : PubMed/NCBI
7	Park JT, Li M, Nakayama K, Mao TL, Davidson B, Zhang Z, Kurman RJ, Eberhart CG, Shih IeM and Wang TL: Notch3 gene amplification in ovarian cancer. Cancer Res. 66:6312–6318. 2006. View Article : Google Scholar : PubMed/NCBI
8	Rose SL, Kunnimalaiyaan M, Drenzek J and Seiler N: Notch 1 signaling is active in ovarian cancer. Gynecol Oncol. 117:130–133. 2010. View Article : Google Scholar : PubMed/NCBI
9	Halder G and Johnson RL: Hippo signaling: Growth control and beyond. Development. 138:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
10	Yu FX and Guan KL: The hippo pathway: Regulators and regulations. Genes Dev. 27:355–371. 2013. View Article : Google Scholar : PubMed/NCBI
11	Santucci M, Vignudelli T, Ferrari S, Mor M, Scalvini L, Bolognesi ML, Uliassi E and Costi MP: The hippo pathway and YAP/TAZ-TEAD protein-protein interaction as targets for regenerative medicine and cancer treatment. J Med Chem. 58:4857–4873. 2015. View Article : Google Scholar : PubMed/NCBI
12	Zaidi SK, Sullivan AJ, Medina R, Ito Y, van Wijnen AJ, Stein JL, Lian JB and Stein GS: Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J. 23:790–799. 2014. View Article : Google Scholar
13	Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, Fuchs CS, Magness ST, Smits R, Ogino S, et al: Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature. 493:106–110. 2013. View Article : Google Scholar : PubMed/NCBI
14	Cai J, Zhang N, Zheng Y, de Wilde RF, Maitra A and Pan D: The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. 24:2383–2388. 2010. View Article : Google Scholar : PubMed/NCBI
15	Hong W and Guan KL: The YAP and TAZ transcription co-activators: Key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 23:785–793. 2012. View Article : Google Scholar : PubMed/NCBI
16	Escoll M, Gargini R, Cuadrado A, Anton IM and Wandosell F: Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ. Oncogene. 36:3515–3527. 2017. View Article : Google Scholar : PubMed/NCBI
17	Ferrarelli LK: Actin against BRAF inhibitors. 9:ec51–ec. 2016.
18	Gayani DM, Kang CH, Hyun CY and Gi-Young K: Mangiferin inhibits tumor necrosis factor-α-induced matrix metalloproteinase-9 expression and cellular invasion by suppressing nuclear factor-κB activity. BMB Rep. 48:559–564. 2015. View Article : Google Scholar : PubMed/NCBI
19	Pan LL, Wang AY, Huang YQ, Luo Y and Ling M: Mangiferin induces apoptosis by regulating Bcl-2 and Bax expression in the CNE2 nasopharyngeal carcinoma cell line. Asian Pac J Cancer Prev. 15:7065–7068. 2014. View Article : Google Scholar : PubMed/NCBI
20	Li H, Huang J, Yang B, Xiang T, Yin X, Peng W, Cheng W, Wan J, Luo F, Li H and Ren G: Mangiferin exerts antitumor activity in breast cancer cells by regulating matrix metalloproteinases, epithelial to mesenchymal transition, and β-catenin signaling pathway. Toxicol Appl Pharmacol. 272:180–190. 2013. View Article : Google Scholar : PubMed/NCBI
21	Louisa M, Soediro TM and Suyatna FD: In vitro modulation of P-glycoprotein, MRP-1 and BCRP expression by mangiferin in doxorubicin-treated MCF-7 cells. Asian Pac J Cancer Prev. 15:1639–1642. 2014. View Article : Google Scholar : PubMed/NCBI
22	Rajendran P, Rengarajan T, Nishigaki I, Ekambaram G and Sakthisekaran D: Potent chemopreventive effect of mangiferin on lung carcinogenesis in experimental Swiss albino mice. J Cancer Res Ther. 10:1033–1039. 2014. View Article : Google Scholar : PubMed/NCBI
23	Shi W, Deng J, Tong R, Yang Y, He X, Lv J, Wang H, Deng S, Qi P, Zhang D and Wang Y: Molecular mechanisms underlying mangiferin-induced apoptosis and cell cycle arrest in A549 human lung carcinoma cells. Mol Med Rep. 13:3423–3432. 2016. View Article : Google Scholar : PubMed/NCBI
24	Zou B, Wang H, Liu Y, Qi P, Lei T, Sun M and Wang Y: Mangiferin induces apoptosis in human ovarian adenocarcinoma OVCAR3 cells via the regulation of Notch3. Oncol Rep. 38:1431–1441. 2017. View Article : Google Scholar : PubMed/NCBI
25	Yimlamai D, Christodoulou C, Galli GG, Yanger K, Pepe-mooney B, Gurung B, Shrestha K, Cahan P, Stanger BZ and Camargo FD: Hippo pathway activity influences liver cell fate. Cell. 157:1324–1338. 2014. View Article : Google Scholar : PubMed/NCBI
26	Schilder RJ, Hall L, Monks A, Handel LM, Fornace AJ Jr, Ozols RF, Fojo AT and Hamilton TC: Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer. 45:416–422. 1990. View Article : Google Scholar : PubMed/NCBI
27	Jayson GC, Kohn EC, Kitchener HC and Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014. View Article : Google Scholar : PubMed/NCBI
28	van Driel WJ, Lok CA, Verwaal V and Sonke GS: The role of hyperthermic intraperitoneal intraoperative chemotherapy in ovarian cancer. Curr Treat Options Oncol. 16:142015.Analgesic and antioxidant activity. View Article : Google Scholar : PubMed/NCBI
29	Dar A, Faizi S, Naqvi S, Roome T, Zikr-ur-Rehman S, Ali M, Firdous S and Moin ST: Analgesic and antioxidant activity of mangiferin and its derivatives: The structure activity relationship. Biol Pharm Bull. 28:596–600. 2005. View Article : Google Scholar : PubMed/NCBI
30	Ajila CM, Rao LJ and Rao UJ: Characterization of bioactive compounds from raw and ripe mangifera indica L. Peel extracts. Food Chem Toxicol. 48:3406–3411. 2010. View Article : Google Scholar : PubMed/NCBI
31	Duang XY, Wang Q, Zhou XD and Huang DM: Mangiferin: A possible strategy for periodontal disease to therapy. Med Hypotheses. 76:486–488. 2011. View Article : Google Scholar : PubMed/NCBI
32	Guha S, Ghosal S and Chattopadhyay U: Antitumor, immunomodulatory and anti-HIV effect of mangiferin, a naturally occurring glucosylxanthone. Chemotherapy. 42:443–451. 1996. View Article : Google Scholar : PubMed/NCBI
33	Iseda S: On Mangiferin, the Coloring Matter of Mango (Mangifera indica Linn.). V. Identification of Sugar Component and the Structure of Mangiferin. Bulletin Chem Soc Japan. 30:629–633. 2006. View Article : Google Scholar
34	Xia Y, Chang T, Wang Y, Liu Y, Li W, Li M and Fan HY: YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PLoS One. 9:e917702014. View Article : Google Scholar : PubMed/NCBI
35	Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB; AOCS Study group, ; Bowtell DD and Harvey KF: The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 30:2810–2822. 2011. View Article : Google Scholar : PubMed/NCBI
36	Hofmann JJ, Zovein AC, Koh H, Radtke F, Weinmaster G and Iruela-Arispe ML: Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: Insights into alagille syndrome. Development. 137:4061–4072. 2010. View Article : Google Scholar : PubMed/NCBI
37	Zong Y, Panikkar A, Xu J, Antoniou A, Raynaud P, Lemaigre F and Stanger BZ: Notch signaling controls liver development by regulating biliary differentiation. Development. 136:1727–1739. 2009. View Article : Google Scholar : PubMed/NCBI
38	Home P, Saha B, Ray S, Dutta D, Gunewardena S, Yoo B, Pal A, Vivian JL, Larson M, Petroff M, et al: Altered subcellular localization of transcription factor TEAD4 regulates first mammalian cell lineage commitment. Proc Natl Acad Sci USA. 109:7362–7367. 2012. View Article : Google Scholar : PubMed/NCBI
39	Rose SL: Notch signaling pathway in ovarian cancer. Int J Gynecol Cancer. 19:564–566. 2009. View Article : Google Scholar : PubMed/NCBI
40	Justice RW, Zilian O, Woods DF, Noll M and Bryant PJ: The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 9:534–546. 1995. View Article : Google Scholar : PubMed/NCBI
41	Pantalacci S, Tapon N and Léopold P: The salvador partner hippo promotes apoptosis and cell-cycle exit in drosophila. Nat Cell Biol. 5:921–927. 2003. View Article : Google Scholar : PubMed/NCBI
42	Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A and Pan D: Elucidation of a universal size-control mechanism in drosophila and mammals. Cell. 130:1120–1133. 2007. View Article : Google Scholar : PubMed/NCBI
43	Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS and Haber DA: Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA. 103:12405–12410. 2006. View Article : Google Scholar : PubMed/NCBI
44	Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA and Anders RA: Expression of Yes-associated protein in common solid tumors. Hum Pathol. 39:1582–1589. 2008. View Article : Google Scholar : PubMed/NCBI
45	Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, et al: Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 125:1253–1267. 2006. View Article : Google Scholar : PubMed/NCBI
46	Takeda T, Tsubaki M, Sakamoto K, Ichimura E, Enomoto A, Suzuki Y, Itoh T, Imano M, Tanabe G, Muraoka O, et al: Mangiferin, a novel nuclear factor kappa B-inducing kinase inhibitor, suppresses metastasis and tumor growth in a mouse metastatic melanoma model. Toxicol Appl Pharmacol. 306:105–112. 2016. View Article : Google Scholar : PubMed/NCBI
47	Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM and Baergen R: Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A gynecologic oncology group study. J Clin Oncol. 21:3194–3200. 2003. View Article : Google Scholar : PubMed/NCBI
48	Giaccone G: Clinical perspectives on platinum resistance. Drugs. 4 Suppl 59:S9–S17. 2000. View Article : Google Scholar
49	Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, et al: The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia. 15:848–862. 2013. View Article : Google Scholar : PubMed/NCBI
50	Liu W, Xie S, Chen X, Rao X, Ren H, Hu B, Yin T, Xiang Y and Ren J: Activation of the IL-6/JAK/STAT3 signaling pathway in human middle ear cholesteatoma epithelium. Int J Clin Exp Pathol. 7:709–715. 2014.PubMed/NCBI
51	Wang SW and Sun YM: The IL-6/JAK/STAT3 pathway: Potential therapeutic strategies in treating colorectal cancer (Review). Int J Oncol. 44:1032–1040. 2014. View Article : Google Scholar : PubMed/NCBI
52	Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland BS, Chang JT, et al: A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 519:57–62. 2015. View Article : Google Scholar : PubMed/NCBI
53	Jeong W, Kim SB, Sohn BH, Park YY, Park ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DSL, et al: Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Res. 34:811–817. 2014.PubMed/NCBI